Advicenne Stock price

Equities

ALDVI

FR0013296746

Pharmaceuticals

Real-time Euronext Paris 06:49:47 2024-03-28 am EDT 5-day change 1st Jan Change
2.145 EUR +1.18% Intraday chart for Advicenne +41.33% -20.30%
Sales 2023 * 3.7M 3.99M Sales 2024 * 4.7M 5.06M Capitalization 26.13M 28.15M
Net income 2023 * -3M -3.23M Net income 2024 * -8M -8.62M EV / Sales 2023 * 9.29 x
Net Debt 2023 * 8.25M 8.89M Net Debt 2024 * 17.4M 18.75M EV / Sales 2024 * 9.26 x
P/E ratio 2023 *
-2.87 x
P/E ratio 2024 *
2.97 x
Employees 19
Yield 2023 *
-
Yield 2024 *
-
Free-Float 88.22%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.19%
1 week+34.00%
Current month+63.95%
1 month+49.78%
3 months-24.15%
6 months-13.36%
Current year-24.44%
More quotes
1 week
1.48
Extreme 1.48
2.39
1 month
1.10
Extreme 1.1
2.39
Current year
1.10
Extreme 1.1
3.08
1 year
1.10
Extreme 1.1
4.70
3 years
1.10
Extreme 1.1
14.30
5 years
1.10
Extreme 1.1
16.25
10 years
1.10
Extreme 1.1
16.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 21-05-02
Chief Tech/Sci/R&D Officer - 23-03-31
Director/Board Member - 17-06-22
Members of the board TitleAgeSince
Chairman - 11-04-28
Director/Board Member 62 17-03-08
Chief Executive Officer 59 21-05-02
More insiders
Date Price Change Volume
24-03-28 2.145 +1.18% 98 054
24-03-27 2.12 +3.67% 45,897
24-03-26 2.045 -11.09% 132,575
24-03-25 2.3 +39.39% 404,396
24-03-22 1.65 +10.00% 89,490

Real-time Euronext Paris, March 28, 2024 at 06:14 am EDT

More quotes
Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children. At the end of 2022, the group had one product in clinical development phase: ADV7103 for the treatment of distal renal tubular acidosis and for the treatment of cystinuria.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.12 EUR
Average target price
6.9 EUR
Spread / Average Target
+225.47%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Advicenne - Euronext Paris